Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sabin-strain inactivated poliovirus vaccine + measles vaccine + mumps vaccine + rubella vaccine
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
sabin-strain inactivated poliovirus vaccine + measles vaccine + mumps vaccine + rubella vaccine is a hexavalent combination vaccine candidate currently under development, most notably by Sinovac Biotech. The vaccine integrates Sabin-strain inactivated poliovirus (sIPV) with live-attenuated measles, mumps, and rubella (MMR) components. The use of Sabin strains for the poliovirus component offers a significant biosafety advantage over traditional Salk-strain IPV, as it utilizes attenuated virus strains rather than wild-type strains during the manufacturing process, aligning with the Global Polio Eradication Initiative's goals. This combination is designed to simplify pediatric immunization schedules by providing protection against six major infectious diseases in a single administration, potentially increasing compliance and reducing logistical burdens in public health programs.
- Other names
- sIPV-MMR vaccinesIPV-MMR combination vaccinesabin-strain IPV + MMR vaccine
02
Targets
Poliovirus type 3 D-antigen epitopes on capsid proteins VP1/VP2/VP3RUBVgp2 (Rubella virus structural polyprotein)Mumps virus structural antigensMV (Measles virus)Poliovirus type 1 D-antigen epitopes on capsid proteins VP1/VP2/VP3Poliovirus type 2 D-antigen epitopes on capsid proteins VP1/VP2/VP3
Beyond the preview
Go deeper on sabin-strain inactivated poliovirus vaccine + measles vaccine + mumps vaccine + rubella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sabin-strain inactivated poliovirus vaccine + measles vaccine + mumps vaccine + rubella vaccine.